Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BSH 2019 | Updates on CAR-T in adult non-Hodgkin lymphoma

Loretta Nastoupil • 2 Apr 2019
BSH 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T Tisagenlecleucel

Loretta Nastoupil, MD, MD Anderson Cancer Center, Houston, TX, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. She gives us the latest updates on CAR-T in adult non-Hodgkin lymphoma.

More from Loretta Nastoupil

NHL: What's hot at ASH 2023?
1:10
NHL: What's hot at ASH 2023?
Loretta Nastoupil • 8 Dec 2023
Tazemetostat + lenalidomide & rituximab vs. lenalidomide & rituximab in patients with R/R FL
2:20
Tazemetostat + lenalidomide & rituximab vs. lenalidomide & rituximab in patients with R/R FL
Loretta Nastoupil • 8 Dec 2023
TRANSCEND FL: liso-cel as 2L therapy in patients with high-risk R/R follicular lymphoma
1:48
TRANSCEND FL: liso-cel as 2L therapy in patients with high-risk R/R follicular lymphoma
Loretta Nastoupil • 8 Dec 2023
Optimizing immunotherapy for 3L or later R/R follicular lymphoma: liso-cel versus mosunetuzumab
1:51
Optimizing immunotherapy for 3L or later R/R follicular lymphoma: liso-cel versus mosunetuzumab
Loretta Nastoupil • 8 Dec 2023

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Loretta Nastoupil • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Loretta Nastoupil • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Loretta Nastoupil • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Loretta Nastoupil • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals